Keyword: Bill Meury

The moment Allergan has been dreading has arrived. Evolus has snagged its OK for a rival to Allergan’s lead moneymaker, Botox.

Despite new competition from CGRP migraine prevention drugs, Allergan executives contend Botox can continue to grow.

Allergan’s Zeltiq has been on a tear as of late, but physicians aren’t expecting that trend to last as long as they once did.

When Allergan CEO Brent Saunders said Wednesday that cost cuts were coming, he didn’t say where. But commercial chief Bill Meury did.

Allergan thinks uterine fibroid treatment Esmya could become a flagship product. But the company knows that getting it there won’t be easy—or cheap.

After years of being recruited, pro athlete Deion Sanders is doing some recruiting of his own—for Botox.

Allergan’s new rosacea treatment Rhofade is gaining insurance coverage—and that means more promotion is on the way.

What’s the best pharma market in the world? According to Allergan CEO Brent Saunders, it’s medical aesthetics.

Allergan knows people inherit lots of traits from their families--and they don't love all of them. That’s the theme of two brand-new DTC ads for chin-fat-fighter Kybella.